Thymosin β4 limits sepsis damage in mice

A May 2026 paper in Biomolecules tested recombinant human thymosin beta-4 (the full-length protein behind the grey-market research chemical TB-500) in a mouse endotoxemia model. Researchers from China's National Key R&D Program gave mice a lethal dose of lipopolysaccharide (LPS, the bacterial toxin used to model sepsis), then treated them with rhTβ4 thirty minutes later. Mice in the treated group survived at an 80% rate at 72 hours^[1].

The paper, authored by Ye, Yang, Liu and colleagues, examined two complications of endotoxemia simultaneously: acute lung injury (ALI), the catastrophic breakdown of the air-exchange surface in the lungs, and endotoxemia-associated encephalopathy (EAE), the neurological impairment that frequently accompanies severe sepsis. Both are major drivers of death and long-term disability in intensive-care patients.

What the study measured

The researchers used two LPS doses: 10 mg/kg for ALI and 5 mg/kg for EAE. rhTβ4 was given at 5 micrograms per kilogram, 0.5 hours after the LPS challenge^[1]. The team then measured cytokine levels in blood and tissue (TNF-alpha, IL-1beta, IL-6, IL-18, IFN-gamma), macrophage polarisation states (the balance between inflammatory M1 and repair-oriented M2 subtypes), and cognition in the EAE mice via novel-object-recognition and Y-maze tests.

RNA sequencing identified lysophosphatidic acid receptor 3 (LPAR3) as a downstream target: rhTβ4 appeared to downregulate LPAR3, which the authors proposed as one mechanism through which the peptide dials back the TLR4/NF-kappaB signalling cascade, the main molecular switch for inflammatory gene expression in macrophages and microglia.

The headline results

In the lung model, rhTβ4 reduced pro-inflammatory cytokine levels, shifted macrophage polarisation away from the M1 (inflammatory) phenotype, and improved histological appearance of lung tissue compared with untreated endotoxemic controls^[1]. In the brain model, treated mice performed significantly better on the novel-object-recognition and Y-maze tests, and microglial activation (neuroinflammation driven by the brain's resident immune cells) was markedly lower.

The 80% survival figure at 72 hours stands out. Mouse endotoxemia at 10 mg/kg LPS is highly lethal in controls (typically below 30% survival at that timeframe), so a treatment administered 30 minutes after the challenge producing 80% survival represents a large effect size in this model system.

Why thymosin beta-4 has this profile

Thymosin beta-4 is a 43-residue peptide found in virtually all nucleated mammalian cells. Its primary job is sequestering G-actin (the soluble form of the structural protein actin), which gives it a role in cell migration and wound healing^[2]. The anti-inflammatory and angiogenic (new blood vessel forming) effects documented across a long preclinical literature are a secondary profile, described in a 2010 review as supporting "current and future clinical applications" in dermal, corneal and cardiac settings^[3].

The only Western-standard human trial data for a thymosin beta-4 formulation is RGN-259, a 0.1% ophthalmic solution tested in a small Phase III trial for neurotrophic keratopathy (a rare corneal condition). That trial reported complete healing in 6 of 10 treated patients at 4 weeks, versus 1 of 8 on placebo, with no significant adverse effects noted^[4].

The corneal formulation is the only one to reach a controlled human trial. Intravenous or subcutaneous use of full-length thymosin beta-4 in humans, as studied in the Biomolecules paper, remains preclinical.

What this research does not show

The Ye et al. paper is a mouse study. Endotoxemia models in rodents have repeatedly produced promising results for compounds that later failed or were never tested in human sepsis trials. The pathway from an LPS-challenged mouse to a critically ill patient is long and routinely breaks down at the pharmacokinetics stage (how the body absorbs and clears the drug), the dose-translation stage, and the endpoint-selection stage (sepsis mortality in humans is driven by factors the mouse model does not replicate).

The study also does not establish safety in humans, a minimum effective dose in humans, or any basis for use outside a research environment. rhTβ4 is not approved by the FDA, the EMA, or any national medicines agency as a systemic medicine for any indication. The paper's framing, that rhTβ4 is a "promising candidate for the treatment of endotoxemia-induced ALI and EAE," is appropriate for a preclinical proof-of-concept, not a treatment recommendation.

How this fits the TB-500 picture

TB-500 is a grey-market label applied online to either full-length thymosin beta-4 (the molecule in the Biomolecules paper) or to AC-LKKTETQ, a short heptapeptide fragment covering amino acids 17-23 of thymosin beta-4. The two are not the same compound at the level of clinical evidence. The Ye et al. findings belong to the full-length recombinant protein, produced under controlled laboratory conditions, not to uncharacterised vials sold as research chemicals. See the TB-500 peptide page for a full breakdown of what is known, what is not known, and what the regulatory picture looks like across the jurisdictions we cover.

The Biomolecules paper adds to a body of preclinical evidence suggesting thymosin beta-4 has genuine biological activity in inflammatory injury models. It does not change the regulatory status, the absence of human efficacy data for systemic use, or the risk profile of grey-market products labelled as TB-500.